KRAS and adenocarcinoma: A panel of lung adenocarcinoma cell lines without targetable genetic alterations, including a KRAS wild‐type (H322), three KRAS mutant (A549, H358 and H460) and a KRAS wild‐type adenocarcinoma‐like mucoepidermoid carcinoma cell line (H292) 26, was selected to further investigate the relationship between EGFR and IFNγ pathway activation with PD‐L1 expression.